FDA approves Eli Lilly's obesity pill

The U.S. Food and Drug Administration has granted approval for Eli Lilly's new obesity medication, Foundayo. This once-daily pill represents the second oral treatment for weight management to receive regulatory clearance, positioning it as a direct competitor to Novo Nordisk's existing pill version of Wegovy. The approval signifies a growing market for pharmacological interventions in obesity treatment and offers patients another therapeutic option.